Article
FDA Moves On Two Fronts: AI Compliance Enforcement And Clinical Trial Innovation
This monthly newsletter examines significant legal trends and landmark cases in tort law, including the Sixth Circuit's reversal of class certification, FDA's dual approach to AI regulation in pharmaceuticals, Minnesota's upcoming PFAS ban, and the Supreme Court's expansive interpretation of federal officer removal jurisdiction. These developments carry strategic implications for businesses navigating complex litigation and regulatory compliance across multiple industries.
Dechert